RVU120: A New Treatment in Clinical Trials for AML, MDS, and Myelofibrosis

What is the new medicine RVU120 by RYVU therapeutics, and how may it help reduce signs/symptoms of AML, MDS, and myelofibrosis? Learn answers to these questions and how you may receive RVU120 in recruiting clinical trials. 

How Does RVU120 Improve AML, MDS, and Myelofibrosis Signs/Symptoms? 

RVU120 helps stem cells (cells capable of forming other blood cells) mature into specialized types, a process called differentiation. This process supports patients affected by cancers that cause issues with the differentiation process, like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). 

Early data from studies testing RVU120 have shown that 50% of heavily pre-treated AML and higher-risk MDS patients who take RVU120 experience improved symptoms, including reduced cancer cells and improved blood cell counts. It is particularly beneficial for patients who have the NPM1 mutation, DNMT3a mutation, and higher-risk MDS. 

For lower-risk MDS, RVU120 helped improve red blood cell counts, enabling some patients to stop needing red blood cell transfusions.  

Another interesting finding from research with RVU120 is that it helped reduce bone marrow scarring seen in myelofibrosis. 

Because of these hopeful insights, RVU120 is advancing in its clinical trial stages for AML, MDS, and myelofibrosis. 

Where Can I Receive RVU120? 

If you have lower-risk MDS, higher-risk MDS, relapsed/refractory AML, or myelofibrosis, learn how you can receive RVU120 in the clinical trials below. For information about how clinical trials work in general, click here. 

Lower-risk MDS 

REMARK study: RVU120 is administered by itself. You’ll receive the medicine for 8 months. The primary goal of this study is to improve your healthy red blood cell levels. Other study goals include reducing patients' need for blood cell transfusions and limiting cancer cell progression. 

Relapsed/refractory AML and higher-risk MDS 

RIVER-52 study: RVU120 is administered by itself. You’ll take RVU120 every other day in cycles of 21 days until you are eligible for an allogeneic stem cell transplant. You’ll need to stop treatment if you experience unmanageable side effects or if the cancer progresses despite therapy.  

Relapsed/refractory AML

RIVER-81 study: RVU120 is given in combination with venetoclax (Venclexta, AbbVie) for AML patients who are relapsed/refractory to prior treatment with venetoclax and a hypomethylating agent (azacitidine [Vidaza, BMS] or decitabine [Dacogen, Astex]). 

Myelofibrosis 

POTAMI-61 study: RVU120 is given alone or in combination with ruxolitinib (Jakafi, Incyte). The study’s main goal is to reduce myelofibrosis-related signs/symptoms. 

Conclusion

In summary, RVU120 is a new medicine in clinical trials for AML, MDS, and myelofibrosis patients. It works by supporting stem cells to properly differentiate. Early data has shown that RVU120 helped patients improve healthy red blood cell counts, decrease cancer cells, and reduce bone marrow scarring. If you are interested in receiving RVU120 to treat your AML, MDS, or myelofibrosis, please see the above clinical trial links. 

Track Your Labs 

Are you interested in keeping track of your labs, such as blood counts, in one place? Click on the link below to access your free account! 

Track My Labs

Sources: 

• Ryvu Therapeutics Clinical Projects Pipeline 

• Ryvu Therapeutics Presents Clinical and Preclinical Data on RVU120 at the 2024 European Hematology Association Congress

• Ryvu Therapeutics Announces Dosing of the First Patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) 

• Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting